Macular oedema related to retinal vascular diseases Level: LLT Classification code 10025415 Term: Macular oedema
Conditions
Sponsors
King's College Hospital NHS Foundation Trust
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 or above 2. Ability to provide informed consent 3. Diagnosis of macular oedema secondary to diabetic maculopathy, branch and central retinal vein occlusion or pseudophakic cystoid macular oedema or post inflammatory macular oedema 4. Central macular thickness on OCT should be above 250µm 5. Best corrected visual acuity in the study eye between 37 and 68 letters Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1. Any other eye disease which could mask macular oedema 2. Known uncontrolled systemic disease or current immunosuppressive disease. 3. Initiation of medical therapy for diabetes or a change from oral hypoglycaemic agents to insulin therapy within 4 months prior to the screening visit 4. Renal failure requiring haemodialysis or peritoneal dialysis within 6 months prior to screening visit 5. Any ocular condition in the study eye that in the opinion of the investigator would prevent a 15-letter improvement in visual acuity (e.g., severe macular ischemia, extensive macular laser scarring or atrophy) 6. Presence of an epiretinal membrane or vitreo-retinal interface changes in the study eye which, in the opinion of the investigator, is the primary cause of macular oedema, or is severe enough to prevent improvement in visual acuity despite reduction in macular oedema 7. Active or suspected ocular or periocular infection including most viral diseases of the cornea and conjunctiva, including active epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, mycobacterial infections, and fungal diseases. 8. Advanced glaucoma which cannot be adequately controlled by medicinal products alone. 9. History of IOP elevation in response to steroid treatment in either eye that resulted in any of the following: a) >10 mm Hg increase in IOP from baseline with an absolute IOP > 25 mm Hg b) required therapy with 3 or more anti-glaucoma medications 10. Pregnancy if child bearing age (confirmed by pregnancy test) and to avoid pregnancy during the 36 weeks of the study. Pregnancy test will not be done in post-menopausal women (defined as 12 months post LMP). Breast feeding women will be excluded. 11. Hypersensitivity to the active substance or to any of the excipients. 12. Inability to provide informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To evaluate the rate of change of macular oedema with intravitreal ozurdex injections in patients with macular oedema;Secondary Objective: Will re-treatment based on recurrence of oedema and decline in vision give better efficiacy outcomes with no new safety concerns? ;Primary end point(s): Mean change in OCT at 4 weekly time points | — |
Countries
United Kingdom
Outcome results
None listed